ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	12/13/1946
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

IGH-BCL2 Fusion, t(14;18) by FISH

ARUP test code 3001298

BCL2 FISH Result	Positive Controls were run and performed as expected. This result has been reviewed and approved by [redacted]
Total Cell Count	621
Scoring Method	Computer Assisted
BCL2 FISH Reference Number	CLS22-53364 A1
BCL2 FISH Source	Omental Mass

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: IGH-BCL2 t(14;18), FISH

IGH-BCL2 fluorescence in situ hybridization (FISH) analysis is designed to detect the IGH-BCL2 fusion associated with t(14;18)(q32;q21). Differentially labeled fluorescent probes directed against IGH and BCL2 were used (Agilent Technologies).

Fused signals within a cell are considered abnormal signal patterns and are consistent with IGH-BCL2 fusion. If a sample contains single fused signals seen in 21 percent or more of the cells, or two or more fused signals in 6 percent or more of the cells evaluated, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of IGH-BCL2 rearrangements in patients with IGH-BCL2-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

IGH-BCL2 fusion is seen in a variety of B-cell lymphomas including follicular lymphomas, diffuse large B-cell lymphomas (DLBCL), and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

Controls performed appropriately.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
BCL2 FISH Result	22-174-151915	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total Cell Count	22-174-151915	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Scoring Method	22-174-151915	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL2 FISH Reference Number	22-174-151915	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL2 FISH Source	22-174-151915	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical